NYSE · TAK
Takeda Pharmaceutical Company Limited
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for TAK has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.31 | $0.31 | $0.31 | 1 |
| Dec 2026 | $0.45 | $0.45 | $0.45 | 1 |
| Mar 2027 | $0.28 | $0.28 | $0.28 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks- Fintel · 3 h agoTakeda Pharmaceutical Company Limited Reports JPY 2,406,997 Million Revenue for the Six-Month Period Ended September 30, 2026Takeda Pharmaceutical Company Limited reported revenue of JPY 2,406,997 million for the six-month period ended September 30, 2026, representing an increase from JPY 2,219,481 million in the same period of the previous year. Net profit for the period rose to JPY 305,716 million, u
- Fintel · 5 h agoTakeda Pharmaceutical Company Limited Reports Revenue of 2,406,997 Million JPY for the Six-month Period Ended September 30, 2026Takeda Pharmaceutical Company Limited reported revenue of 2,406,997 million JPY and operating profit of 406,739 million JPY for the six-month period ended September 30, 2026. This represents a revenue increase of 8.4% on an Actual Exchange Rate basis compared to the six-month per
- RTTNews · 7 h agoTakeda H1 EPS Surges, Revenue Up 8.4%; Upgrades FY26 Outlook(RTTNews) – Takeda Pharmaceutical Company Ltd. (TAK), Thursday reported a 171.8 percent surge in first half earnings compared to the prior year. Looking ahead to the full year 2026, the company raised its outlook.
- RTTNews · Oct 19, 10:57 AM EDTTakeda's ENTYVIO Treat-To-Target Trial Reduces UC Complication Risk By Nearly 70%; Stock Down(RTTNews) – Takeda Pharmaceutical Company Limited (TAK) announced results from the Phase 4 VERDICT trial showing that treating adults with moderate to severe ulcerative colitis (UC) with ENTYVIO (vedolizumab) to achieve disease clearance significantly prolonged the time to first
- RTTNews · Oct 19, 7:04 AM EDTTakeda Reports Positive New Data Of VERDICT Phase 4 ENTYVIO Trial In Ulcerative Colitis(RTTNews) – Japan's Takeda Pharmaceutical Co. Ltd. (TAK,4502.T) announced Monday positive new data from VERDICT (NCT04259138), a Phase 4 ENTYVIO clinical trial, in ulcerative colitis or UC-related complication.
- RTTNews · Oct 14, 11:36 PM EDTTakeda Launches ORZEYFUL For Narcolepsy Type 1 In Japan, China; Stock Up(RTTNews) – Takeda Pharmaceutical Company Ltd. (TAK,4502.T), which explores orexin science, announced on Thursday that ORZEYFUL (oveporexton) is now available in Japan and China to treat Narcolepsy Type 1 (NT1), with clinicians gaining first access to prescribe this new class of
- RTTNews · Oct 14, 9:33 AM EDTTakeda's TAK-881 Cuts Infusion Time By 42.6% In Phase 3 PID Study(RTTNews) – Takeda Pharmaceutical Company Limited (TAK), a biopharmaceutical company developing treatments for rare diseases and other conditions, presented detailed Phase 2/3 IgGNITE study results for its investigational subcutaneous therapy TAK-881 in patients with Primary Immu
- RTTNews · Sep 30, 2:58 AM EDTTakeda Says Zasocitinib Tops Deucravacitinib With Superior Skin Clearance In Phase 3 Trial(RTTNews) – Takeda Pharmaceutical Company Ltd. (TAK, 4502.T) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis.
- RTTNews · Sep 30, 2:03 AM EDTTakeda's Zasocitinib Shows Superior Skin Clearance In Phase 3 Psoriasis Trial(RTTNews) – Takeda Pharmaceutical Company Ltd. (TAK,4502.T) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis.
- Zacks · Sep 29, 9:17 AM EDTKROS Begins Dosing in Phase II Study With Rinvatercept in DMDKeros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.
- RTTNews · Sep 28, 1:49 AM EDTInnovent Expands Phase 3 IBI363 Study To Non-Squamous Lung Cancer; Stock Down(RTTNews) – Innovent Biologics, Inc. (1801.HK), a biopharmaceutical company focused on developing therapies across oncology and other major diseases, announced the expansion of the global Phase 3 MarsLight-11 study of IBI363/TAK-928 to include patients with non-squamous non-small
- RTTNews · Sep 21, 1:39 AM EDTTakeda Unveils $22.2 Mln CSR Collaborations Focused On Climate-Resilient Health; Stock Up(RTTNews) – Takeda Pharmaceutical Company Ltd. (TAK), a commercial-stage pharmaceutical company announced that it has granted $22.2 million to four new Corporate Social Responsibility (CSR) partners to support climate-resilient health systems in low- and middle-income countries.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Takeda Pharmaceutical Company Limited from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.